Drug use in 17-year-olds: analysis of the ESCAPAD survey 



Tendances n° 100, OFDT, 8 p.
May 2015

Set up in 2000 by the OFDT in partnership with the National Service Directorate (DSN), the ESCAPAD survey has been focusing on late adolescence, providing information on a crucial period for psychoactive substance use in the general population. From 17 to 21 March 2014, the eighth ESCAPAD survey was conducted, with 26,351 French adolescents questioned about their health and their use of psychoactive substances. Issue 100 of Tendances (“Trends”) presents the changing trends in the use of psychoactive substances (both legal and illegal) over the past fifteen years in mainland France, incorporating 2014 data on alcoholic beverage, tobacco and cannabis use. It then examines, from a variety of perspectives, new questions concerning the use of e-cigarettes, shisha, the evolution in regular polydrug use and offers an estimate of the proportion of cannabis users who are potentially dependent. The last section covers the social and family factors associated with regular use.

Authors : Stanislas Spilka, Olivier Le Nézet, Marcus Ngantcha, François Beck

Download the PDF file (615 Ko)










Drugs in Europe

2021 EMCDDA European Drug Report

How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
Drug markets
What do the latest data tell us about drug production and trafficking trends?

These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.

  Statistical Bulletin 2021

The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.